215 related articles for article (PubMed ID: 31315441)
1. Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets.
Chen 陈温纯 W; Voos KM; Josephson CD; Li R
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2028-2037. PubMed ID: 31315441
[TBL] [Abstract][Full Text] [Related]
2. Refrigeration-Induced Binding of von Willebrand Factor Facilitates Fast Clearance of Refrigerated Platelets.
Chen W; Druzak SA; Wang Y; Josephson CD; Hoffmeister KM; Ware J; Li R
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2271-2279. PubMed ID: 29097365
[TBL] [Abstract][Full Text] [Related]
3. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
4. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
[TBL] [Abstract][Full Text] [Related]
5. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
Diener JL; Daniel Lagassé HA; Duerschmied D; Merhi Y; Tanguay JF; Hutabarat R; Gilbert J; Wagner DD; Schaub R
J Thromb Haemost; 2009 Jul; 7(7):1155-62. PubMed ID: 19422452
[TBL] [Abstract][Full Text] [Related]
7. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
[TBL] [Abstract][Full Text] [Related]
8. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gorczyca ME; Jilma B; Siller-Matula J; Gilbert JC; Knöbl P
Thromb Haemost; 2011 Mar; 105(3):545-52. PubMed ID: 21174003
[TBL] [Abstract][Full Text] [Related]
10. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gilbert JC; Gorczyca ME; Knöbl P; Jilma B
Thromb Haemost; 2011 Sep; 106(3):539-47. PubMed ID: 21833442
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting GPIbα Shedding Preserves Post-Transfusion Recovery and Hemostatic Function of Platelets After Prolonged Storage.
Chen W; Liang X; Syed AK; Jessup P; Church WR; Ware J; Josephson CD; Li R
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1821-8. PubMed ID: 27417583
[TBL] [Abstract][Full Text] [Related]
12. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect.
Castillo R; Escolar G; Monteagudo J; Aznar-Salatti J; Reverter JC; Ordinas A
Transfusion; 1997 Aug; 37(8):785-90. PubMed ID: 9280321
[TBL] [Abstract][Full Text] [Related]
13. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
Knöbl P; Jilma B; Gilbert JC; Hutabarat RM; Wagner PG; Jilma-Stohlawetz P
Transfusion; 2009 Oct; 49(10):2181-5. PubMed ID: 19538431
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice.
Groeneveld D; Cline-Fedewa H; Baker KS; Williams KJ; Roth RA; Mittermeier K; Lisman T; Palumbo JS; Luyendyk JP
J Hepatol; 2020 Jan; 72(1):146-155. PubMed ID: 31606553
[TBL] [Abstract][Full Text] [Related]
15. Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.
Sakai K; Someya T; Harada K; Yagi H; Matsui T; Matsumoto M
Haematologica; 2020 Nov; 105(11):2631-2638. PubMed ID: 33131252
[TBL] [Abstract][Full Text] [Related]
16. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.
Kanaji S; Fahs SA; Shi Q; Haberichter SL; Montgomery RR
J Thromb Haemost; 2012 Aug; 10(8):1646-52. PubMed ID: 22642380
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients.
Castillo R; Monteagudo J; Escolar G; Ordinas A; Magallón M; Martín Villar J
Blood; 1991 May; 77(9):1901-5. PubMed ID: 1902120
[TBL] [Abstract][Full Text] [Related]
18. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
Bae ON
Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
[TBL] [Abstract][Full Text] [Related]
19. The Use of Fluorescently Labeled ARC1779 Aptamer for Assessing the Effect of H2O2 on von Willebrand Factor Exocytosis.
Avdonin PP; Trufanov SK; Rybakova EY; Tsitrina AA; Goncharov NV; Avdonin PV
Biochemistry (Mosc); 2021 Feb; 86(2):123-131. PubMed ID: 33832411
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
Nimjee SM; Dornbos D; Pitoc GA; Wheeler DG; Layzer JM; Venetos N; Huttinger A; Talentino SE; Musgrave NJ; Moody H; Rempel RE; Jones C; Carlisle K; Wilson J; Bratton C; Joseph ME; Khan S; Hoffman MR; Sommerville L; Becker RC; Zweier JL; Sullenger BA
Mol Ther; 2019 Jul; 27(7):1228-1241. PubMed ID: 30987839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
